Focused On-demand Library for SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library is unique due to several crucial aspects:

Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.
By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.
The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.
Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

partner

Reaxense

upacc

Q96GM5

UPID:

SMRD1_HUMAN

Alternative names:

60 kDa BRG-1/Brm-associated factor subunit A; BRG1-associated factor 60A; SWI/SNF complex 60 kDa subunit

Alternative UPACC:

Q96GM5; A6NN27; Q92924; Q9Y635

Background:

SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1, also known as SWI/SNF complex 60 kDa subunit, plays a pivotal role in chromatin remodeling. This protein is a key component of the SWI/SNF chromatin remodeling complexes, which modify chromatin structure to regulate gene expression. It is involved in transcriptional activation and repression, and is crucial for neural development, transitioning neural stem cells into neurons.

Therapeutic significance:

The protein's involvement in Coffin-Siris syndrome 11, characterized by developmental delay and intellectual disability, underscores its therapeutic significance. Understanding the role of SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily D member 1 could open doors to potential therapeutic strategies for this and related disorders.